Fisher & Paykel Healthcare Investors Should Focus on Tariff Impacts Ahead of Fiscal H1 Results, Says Jefferies
MT Newswires Live
Nov 14, 2025
Fisher & Paykel Healthcare (ASX:FPH, NZE:FPH) investors should focus on tariff impacts and consequences for the gross margin trajectory, sales growth, and any early-season flu read-through, ahead of the company's fiscal first-half results, according to a Thursday Jefferies note.
The investment firm added that with a warm winter predicted for the US, it is interested in early disease experience, noting that less than 5% of FPH's hospital business is typically due to seasonal effects.
Jefferies maintained its buy rating on FPH and raised its price target to NZ0$44.40 from NZ$40.90.
Fisher & Paykel Healthcare's Australian shares shed about 1% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.